Abstract:

Objective To evaluate the efficacy and safety of the combination of gemcitabine and docetaxel in patients with recurrent or refractory osteosarcoma. Methods Twenty-eight patients with recurrent or refractory osteosarcoma confirmed by histopathology were administrated with gemcitabine 1000mg／m²（day 1 and day 8） and docetaxel 75mg／m²（day 8） every 3 weeks. The overall response and toxicity were observed.
ResultsTotally， 28 patients were entered and all of these patients were evaluated. Partial response was observed in 1 patient， stable disease was observed in 8 patients and progressive disease was observed in 19 patients. Overall response rate was 3.6％（1／28） and the disease control rate was 32.1％（9／28）. Median time to progression and overall survival time were 6.0 weeks（6.24） and 11.0 months（3.26）， respectively. The main toxic reactions were myelosuppression, digestive tract reaction and fatigue. No serious adverse event was observed. Conclusion The gemcitabine combined with docetaxel tends to show modest treatment efficacy and is well tolerated in patients with recurrent or refractory osteosarcoma.